SCHEMBL476853

SCHEMBL476853

CC1(C)OB(c2cccc3[nH]ccc23)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.42
PIK3CD O00329 1/20 0.36
JAK2 O60674 3/20 0.35
BTK Q06187 3/20 0.35
LPL P06858 2/20 0.35
LIPG Q9Y5X9 2/20 0.35
RHEB Q15382 4/20 0.34
MAPK1 P28482 1/20 0.34
ADRB1 P08588 1/20 0.34
HTR6 P50406 1/20 0.34
NR3C1 P04150 1/20 0.33
PGR P06401 1/20 0.33
GAA P10253 1/20 0.33
CCR4 P51679 1/20 0.33
HTR1B P28222 1/20 0.33
DAO P14920 1/20 0.32
DRD2 P14416 1/20 0.32
DRD4 P21917 1/20 0.32
DRD3 P35462 1/20 0.32
TRPA1 O75762 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29374726 1.00 AHR (0.42) AHRPIK3CDJAK2BTKLPL
SCHEMBL2173162 0.80 PARP1 (0.46) JAK2BTK
SCHEMBL30667750 0.80 PARP1 (0.46) JAK2BTK
SCHEMBL3191660 0.80 AHR (0.39) AHRPIK3CDRHEBMAPK1ADRB1
SCHEMBL13363796 0.79 AHR (0.36) AHRPIK3CDRHEBMAPK1ADRB1
SCHEMBL29414051 0.78 ATM (0.44) AHRLPLLIPGADRB1HTR6
SCHEMBL2111365 0.78 ATM (0.44) AHRLPLLIPGADRB1HTR6
SCHEMBL13527502 0.78 LPL (0.44) JAK2BTKLPLLIPGMAPK1
SCHEMBL12926609 0.78 CSF1R (0.31) LPLLIPG
SCHEMBL1565470 0.78 LPL (0.36) JAK2BTKLPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7507262-B2 Compositions for oxidatively dyeing keratin fibers and methods for using such compositions THE PROCTER & GAMBLE COMPANY (US) 2009-03-24 US claimed
US-20070209123-A1 Compositions for oxidatively dyeing keratin fibers and methods for using such compositions THE PROCTER & GAMBLE COMPANY 2007-09-13 US claimed
US-12398132-B2 Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents AUCENTRA THERAPEUTICS PTY LTD (AU) 2025-08-26 US disclosed
EP-4045506-B1 DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS AUCENTRA THERAPEUTICS PTY LTD (AU) 2025-07-23 EP disclosed
US-20250179046-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC 2025-06-05 US disclosed
WO-2025098450-A1 PRMT5 INHIBITOR AND PREPARATION METHOD THEREFOR 北京泰德制药股份有限公司 2025-05-15 WO disclosed
EP-4090661-B1 QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR GRUENENTHAL GMBH (DE) 2025-03-12 EP disclosed
US-12240827-B2 Serotonin 5-HT2B inhibitory compounds ZOETIS SERVICES LLC (US) 2025-03-04 US disclosed
US-20240336601-A1 4-PHENYL-INDOLE DERIVATIVES AND RELATED USES CHULALONG UNIVERSITY (TH) 2024-10-10 US disclosed
US-12110293-B2 Substituted triazolo quinoxaline derivatives Grünenthal GmbH (DE) 2024-10-08 US disclosed
EP-3630770-B1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS RELAY THERAPEUTICS INC (US) 2024-08-28 EP disclosed
US-20040097497-A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors SUGEN, INC. 2004-05-20 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-6635640-B2 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors SUGEN, INC. 2003-10-21 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
EP-1296975-A1 4-HETEROARYL-3-HETEROARYLIDENYL-2-INDOLINONES AND THEIR USE AS PROTEIN KINASE INHIBITORS Sugen, Inc. (US) 2003-04-02 EP disclosed
US-20020187978-A1 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors SUGEN, INC. 2002-12-12 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed
WO-2002002551-A1 4-HETEROARYL-3-HETEROARYLIDENYL-2-INDOLINONES AND THEIR USE AS PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240827-B2 Serotonin 5-HT2B inhibitory compounds HTR2B, HTR1B, HTR5A AHR 2264/4885PIK3CD 2144/4885JAK2 893/4885
US-20250179046-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS HTR2B, HTR1B, HTR5A AHR 2264/4885PIK3CD 2144/4885JAK2 893/4885
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 AHR 656/4885PIK3CD 365/4885JAK2 127/4885
US-20020187978-A1 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors CDK2, CDK20, CDK3 AHR 1217/4885PIK3CD 214/4885JAK2 354/4885
US-20040097497-A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors CDK2, CDK20, CDK3 AHR 1217/4885PIK3CD 214/4885JAK2 354/4885
US-20240336601-A1 4-PHENYL-INDOLE DERIVATIVES AND RELATED USES PDCD1, PDCD1LG2, CD274 AHR 28/4885PIK3CD 1437/4885JAK2 347/4885
US-12398132-B2 Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents FLT3, CDK2, CDK4 AHR 731/4885PIK3CD 271/4885JAK2 78/4885
US-20070209123-A1 Compositions for oxidatively dyeing keratin fibers and methods for using such compositions KRT18, AKR7A2, AKR1C4 AHR 71/4885PIK3CD 2565/4885JAK2 4376/4885
US-12110293-B2 Substituted triazolo quinoxaline derivatives NR3C1, NR3C2, GRK5 AHR 1241/4885PIK3CD 3160/4885JAK2 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.